Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer

被引:77
作者
De Jaeger, K
Seppenwoolde, Y
Boersma, LJ
Muller, SH
Baas, P
Belderbos, JSA
Lebesque, JV
机构
[1] Netherlands Canc Inst, Antoni van Leeuvenhoek Hosp, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Antoni van Leeuvenhoek Hosp, Dept Nucl Med, NL-1066 CX Amsterdam, Netherlands
[3] Netherlands Canc Inst, Antoni van Leeuvenhoek Hosp, Dept Chest Oncol, NL-1066 CX Amsterdam, Netherlands
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2003年 / 55卷 / 05期
关键词
pulmonary function; SPECT; perfusion; tumor response; mean lung dose;
D O I
10.1016/S0360-3016(02)04389-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To study changes of pulmonary function tests (PFTs) after radiotherapy (RT) of non-small-cell lung cancer (NSCLC) in relation to radiation dose, tumor regression, and changes in lung perfusion. Methods and Materials: Eighty-two patients with inoperable NSCLC were evaluated with PFTs (forced expiratory volume in 1 s [FEVt] and diffusion capacity [T-L,T-COc]), a computed tomography (CT) scan of the chest, and a single photon emission CT (SPECT) lung perfusion scan, before and 3-4 months after RT. The reductions of PFTs and tumor volume were calculated. The lung perfusion was measured from pre- and post-RT SPECT scans, and the difference was defined as the measured perfusion reduction (MPR). In addition, the perfusion post-RT was estimated from the dose distribution using a dose-effect relation for regional lung perfusion, and compared with the pre-RT lung perfusion to obtain the predicted perfusion reduction (PPR). The difference between the actually measured and the PPR was defined as reperfusion. The mean lung dose (MLD) was computed and weighted with the pre-RT perfusion, resulting in the mean perfusion-weighted lung dose (MpLD). Changes of PFTs were evaluated in relation to tumor dose, MLD, MpLD, tumor regression, and parameters related to perfusion changes. Results: In a multivariate analysis, the total tumor dose and MLD were not associated with reductions of PFTs. Tumor regression resulted in a significant improvement of FEV1 (p = 0.02), but was associated with a reduction of T-L,T-COc. (P = 0.05). The MpLD and the PPR showed a significant (p = 0.01 to 0.04) but low correlation (r = 0.24 to 0.31) with the reduction of both PFTs. The other parameters for perfusion changes, the MPR and reperfusion were not correlated with changes in PFTs. Conclusion: The perfusion-related dose variables, the MpLD or the PPR, are the best parameters to estimate PFTs after RT. Tumor regression is associated with an improvement of FEV1 and a decline of T-L,T-COc. Reperfusion was not associated with an improvement of global pulmonary function. (C) 2003 Elsevier Science Inc.
引用
收藏
页码:1331 / 1340
页数:10
相关论文
共 50 条
  • [31] Radiation pneumonitis in non-small-cell lung cancer patients treated with helical tomotherapy
    Yao, B.
    Wang, Y. D.
    Liu, Q. Z.
    NIGERIAN JOURNAL OF CLINICAL PRACTICE, 2016, 19 (01) : 25 - 29
  • [32] Impact and Safety of Adjuvant Chemotherapy on Pulmonary Function in Early Stage Non-Small Cell Lung Cancer
    Kreuter, Michael
    Vansteenkiste, Johan
    Herth, Felix J. F.
    Fischer, Juergen R.
    Eberhardt, Wilfried
    Zuna, Ivan
    Reinmuth, Niels
    Griesinger, Frank
    Thomas, Michael
    RESPIRATION, 2014, 87 (03) : 204 - 210
  • [33] CURATIVE TREATMENT OF STAGE I NON-SMALL-CELL LUNG CANCER IN PATIENTS WITH SEVERE COPD: STEREOTACTIC RADIOTHERAPY OUTCOMES AND SYSTEMATIC REVIEW
    Palma, David
    Lagerwaard, Frank
    Rodrigues, George
    Haasbeek, Cornelis
    Senan, Suresh
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (03): : 1149 - 1156
  • [34] Pulmonary function after high-dose chemotherapy with autologous bone marrow transplantation and radiotherapy in patients with advanced loco-regional breast cancer
    Dolsma, WV
    DeVries, EGE
    VanderMark, TW
    Sleijfer, DT
    Willemse, PHB
    VanderGraaf, WTA
    Mulder, POM
    Szabo, BG
    Mulder, NH
    ANTICANCER RESEARCH, 1997, 17 (1B) : 537 - 540
  • [35] Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancer
    Abbott, Annalise G.
    Meyers, Daniel E.
    Elmi-Assadzadeh, Golpira
    Stukalin, Igor
    Marro, Alessandro
    Puloski, Shannon K. T.
    Morris, Don G.
    Cheung, Winson Y.
    Monument, Michael J.
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [36] Changes in Pulmonary Function After Stereotactic Body Radiotherapy and After Surgery for Stage I and II Non-small Cell Lung Cancer, a Description of Two Cohorts
    Alberts, Leonie
    El Sharouni, Sherif Y.
    Hofman, Frederik N.
    Van Putte, Bart P.
    Tromp, Ellen
    Van Vulpen, Marco
    Kastelijn, Elisabeth A.
    Schramel, Franz M. N. H.
    ANTICANCER RESEARCH, 2015, 35 (12) : 6773 - 6779
  • [37] Effect of early palliative care on quality of life in patients with non-small-cell lung cancer
    Zhuang, H.
    Ma, Y.
    Wang, L.
    Zhang, H.
    CURRENT ONCOLOGY, 2018, 25 (01) : E54 - E58
  • [38] Impact of intrapulmonary tumour location of non-small-cell lung cancer on surgical outcomes for segmentectomy
    Matsui, Takuya
    Takahashi, Yusuke
    Nakada, Takeo
    Sugita, Yusuke
    Seto, Katsutoshi
    Sakakura, Noriaki
    Mizuno, Kotaro
    Haneda, Hiroshi
    Okuda, Katsuhiro
    Kuroda, Hiroaki
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2024, 65 (03)
  • [39] Radiotherapy issues in non-small cell lung cancer: radiotherapy versus surgery in the treatment of early stage
    Jimenez, M. F.
    Varela, G.
    Van Baardwijk, A.
    De Ruysscher, D.
    MINERVA CHIRURGICA, 2011, 66 (03) : 245 - 250
  • [40] Outcomes and pulmonary function after sleeve lobectomy compared with pneumonectomy in patients with non-small cell lung cancer
    Matsuo, Tsubasa
    Imai, Kazuhiro
    Takashima, Shinogu
    Kurihara, Nobuyasu
    Kuriyama, Shoji
    Iwai, Hidenobu
    Tozawa, Kasumi
    Saito, Hajime
    Nomura, Kyoko
    Minamiya, Yoshihiro
    THORACIC CANCER, 2023, 14 (09) : 827 - 833